Pre-clinical trials also addressed the effects of p62 plasmid in a model of senescence-accelerating OXYS rats, an animal model that spontaneously develops AMD-like retinopathy with clinical signs more evident at 12 months or later [52]. Here, SQSTM1 is linked to retinal disorder.